Biotech & Healthtech Funding May–June 2026: ADCs, Immune Mapping, and AI Care
Anagram Therapeutics, Ona Therapeutics, IMU Biosciences, and Garner Health show biotech and healthtech capital in 2026 favoring validated science and AI-enabled care.
Healthtech venture capital spans digital health platforms, care delivery innovation, diagnostics, and AI-enabled clinical workflows. Our healthtech coverage tracks the funding rounds and fund strategies defining the next generation of healthcare technology.
Browse healthtech venture capital articles below.
Anagram Therapeutics, Ona Therapeutics, IMU Biosciences, and Garner Health show biotech and healthtech capital in 2026 favoring validated science and AI-enabled care.
New York-based Dimension Capital filed SEC Form D in June 2026 seeking up to $750M for its third fund, following $350M Fund I and $500M Fund II.
UK biotech IMU Biosciences extended its oversubscribed Series A past $53M in June 2026 to map and decode the human immune system for drug discovery.
Barcelona biopharma Ona Therapeutics closed an oversubscribed $86.6M Series B in June 2026 to advance first-in-class antibody-drug conjugates for resistant cancers.
UK healthcare-tech company Semble raised a £30M Series C led by Revaia in June 2026, scaling its practice-management platform for clinicians.
Garner Health raised $100M Series E led by Index Ventures in May 2026 at a $2.74B valuation, scaling its data platform for finding high-quality healthcare providers.